Neogenomics: Other Events

The following excerpt is from the company's SEC filing.

On April 22, 2014, NeoGenomics, Inc. (“NeoGenomics” or the “Company”) entered into a Second Amended and Restated Strategic Laboratory Services Agreement (the “Agreement”) with Florida Cancer Specialists, P.L. (“FCS”). Under the terms of the Agreement, FCS agreed that, subject to certain exceptions, it would first offer to have NeoGenomics perform all cytogenetics and molecular testing services on cancer specimens from FCS’s 72 practice locations before either performing such services in its own laboratory or referring such specimens to other laboratories. FCS also agreed, subject to certain exceptions, that it wou ld first offer to have NeoGenomics perform any other cancer genetic testing services not otherwise performed by FCS’s internal laboratory before referring such specimens to other laboratories. NeoGenomics agreed to perform all accessioning and customer service functions and provide certain other services relating to cancer genetics testing for all of FCS’s practice locations. The Agreement extends the current contract through December 31, 2015, but will automatically renew for additional one year terms thereafter, unless either party gives the other party six months’ prior written notice.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here. Neogenomics Inc. next reports earnings on April 23, 2014.

To receive a free e-mail notification whenever Neogenomics Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Current report, items 2.02 and 9.01 - Feb. 24, 2015
Statement of acquisition of beneficial ownership by individuals - Feb. 5, 2015

   Auto Refresh